Flip flop policy over pioglitazone licence causes media storm in India

India’s ministry of health and family welfare has revoked the ban that it placed on the antidiabetes drug pioglitazone just six weeks ago because of the drug’s association with bladder cancer.1

…. India has one of the largest universal immunization programs in the world with 26 million babies born every year. Approximately 10% to 20% of immunizations, totalling to at least 3 to 5 million infants annually, are through the private sector. But despite national guidelines that say public and the private healthcare systems must both take part in surveillance of immunisations “reporting from private sector is limited so far,” says the paper.

Read the full article by Dr. Soumyadeep B at  the British Medical Journal

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s